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BACKGROUND
Mass administration of azithromycin for trachoma control led to a sustained reduc-
tion in all-cause mortality among Ethiopian children. Whether the addition of 
azithromycin to the monthly sulfadoxine–pyrimethamine plus amodiaquine used for 
seasonal malaria chemoprevention could reduce mortality and morbidity among 
African children was unclear.
METHODS
We randomly assigned children 3 to 59 months of age, according to household, to 
receive either azithromycin or placebo, together with sulfadoxine–pyrimethamine 
plus amodiaquine, during the annual malaria-transmission season in Burkina Faso 
and Mali. The drug combinations were administered in four 3-day cycles, at month-
ly intervals, for three successive seasons. The primary end point was death or hospital 
admission for at least 24 hours that was not due to trauma or elective surgery. Data 
were recorded by means of active and passive surveillance.
RESULTS
In July 2014, a total of 19,578 children were randomly assigned to receive seasonal 
malaria chemoprevention plus either azithromycin (9735 children) or placebo 
(9843 children); each year, children who reached 5 years of age exited the trial and 
new children were enrolled. In the intention-to-treat analysis, the overall number of 
deaths and hospital admissions during three malaria-transmission seasons was 
250 in the azithromycin group and 238 in the placebo group (events per 1000 child-
years at risk, 24.8 vs. 23.5; incidence rate ratio, 1.1; 95% confidence interval [CI], 
0.88 to 1.3). Results were similar in the per-protocol analysis. The following events 
occurred less frequently with azithromycin than with placebo: gastrointestinal 
infections (1647 vs. 1985 episodes; incidence rate ratio, 0.85; 95% CI, 0.79 to 0.91), 
upper respiratory tract infections (4893 vs. 5763 episodes; incidence rate ratio, 
0.85; 95% CI, 0.81 to 0.90), and nonmalarial febrile illnesses (1122 vs. 1424 episodes; 
incidence rate ratio, 0.79; 95% CI, 0.73 to 0.87). The prevalence of malaria parasit-
emia and incidence of adverse events were similar in the two groups.
CONCLUSIONS
Among children in Burkina Faso and Mali, the addition of azithromycin to the 
antimalarial agents used for seasonal malaria chemoprevention did not result in a 
lower incidence of death or hospital admission that was not due to trauma or surgery 
than antimalarial agents plus placebo, although a lower disease burden was noted with 
azithromycin than with placebo. (Funded by the Joint Global Health Trials scheme; 
ClinicalTrials.gov number, NCT02211729.)
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Malaria transmission is concen-trated during a few months of the year in much of the Sahel and sub-Sahel re-
gions of Africa. In these areas, seasonal malaria 
chemoprevention — the administration of sulfa-
doxine–pyrimethamine plus amodiaquine to chil-
dren at monthly intervals three or four times dur-
ing the malaria-transmission season — has been 
a highly effective approach to malaria control.1 
Seasonal malaria chemoprevention is now being 
implemented widely across these regions.2 The 
frequent contact between children and health 
care workers that is needed for seasonal malaria 
chemoprevention provides an opportunity for the 
delivery of other health interventions.
Mass administration of azithromycin has been 
a highly effective approach to trachoma control.3 
Reductions in the incidences of skin, gastrointes-
tinal, and respiratory infections have been record-
ed after mass administration of azithromycin.4-8 
Nevertheless, the finding in Ethiopia of a 49% re-
duction in all-cause mortality among children 1 to 
9 years of age during the year after mass admin-
istration of a single dose of azithromycin — a re-
duction that was sustained during a 26-month 
follow-up period — was surprising.9,10 Conse-
quently, we conducted a randomized, double-blind, 
placebo-controlled trial to determine whether the 
addition of azithromycin to the sulfadoxine–pyri-
methamine plus amodiaquine given for seasonal 
malaria chemoprevention could have a similar ef-
fect on overall child mortality and morbidity.
Me thods
Trial Oversight
The trial was approved by the ethics committees 
of the London School of Hygiene and Tropical 
Medicine, London; the Malaria Research and 
Training Center, University of Bamako, Bamako, 
Mali; the Ministry of Health, Ouagadougou, 
Burkina Faso; and the national regulatory au-
thorities of Burkina Faso and Mali. A data and 
safety monitoring board reviewed serious adverse 
events, monitored the overall progress of the trial, 
approved the statistical analysis plan, and archived 
the locked database before the data were un-
masked. A steering committee reviewed the proto-
col (available with the full text of this article at 
NEJM.org) and provided overall advice. The 
authors vouch for the accuracy and completeness 
of the data and the fidelity of the trial to the 
protocol.
Sites and Population
The trial was conducted in the Houndé district 
of Burkina Faso and in the Bougouni district of 
Mali (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). Information about these 
communities and the children who live in them 
is provided in the protocol and the Supplemen-
tary Appendix.
Enrollment and Randomization
A household census was conducted in June 2014, 
and children of either sex who were 3 to 59 months 
of age on August 1, 2014, were eligible for enroll-
ment in the trial. After written informed consent 
was obtained from the child’s parent or guard-
ian, the child received a long-lasting insecticide-
treated bed net. Children were excluded if they 
had a chronic disease or a known allergy to 
sulfadoxine–pyrimethamine, amodiaquine, or 
azithromycin or if they were taking cotrimoxa-
zole. The household census was repeated in May 
2015 and in May 2016 to recruit additional eli-
gible children and to detect any deaths that had 
been missed through the surveillance system. 
Each year, children who were still younger than 
60 months of age on August 1 remained in fol-
low-up for the subsequent trial year, and children 
who had reached 5 years of age on or before July 
31 exited the trial on that date. Enrollment of 
children in the trial started on August 25, 2014, 
in Mali and on August 28, 2014, in Burkina Faso.
Randomization was performed according to 
household to avoid the potential effect of within-
household transmission of infection; all eligible 
children who shared a kitchen were assigned to 
the same trial group. To mask the trial-group 
assignments for the trial team and caregivers, a 
placebo for azithromycin of identical appearance 
was used.
Interventions
Children who were enrolled in the trial received 
the assigned preventive regimen during the annual 
peak malaria-transmission season (August to No-
vember). The drug combinations were adminis-
tered in four 3-day cycles, at monthly intervals, for 
three successive seasons. Infants 3 to 11 months 
of age received a combined 250 mg of sulfadox-
ine and 12.5 mg of pyrimethamine plus 75 mg 
of amodiaquine on day 1 and received 75 mg of 
amodiaquine on days 2 and 3 (Guilin Pharmaceu-
tical, Shanghai, China). In addition, they were 
randomly assigned to receive either 100 mg of 
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azithromycin or matching placebo on days 1, 2, 
and 3 (Cipla, Mumbai, India). Children 1 to 4 years 
of age received double these doses. All doses were 
based on age and administered by trial staff. All 
trial drugs were purchased from the manufactur-
ers with the use of a grant provided by the U.K. 
Medical Research Council and were provided to 
the children free of cost.
Each year, the drug combinations were pre-
packed in resealable plastic bags by pharmacists 
who were not part of the trial team. Each child 
was assigned one large bag that contained four 
smaller bags, each of which contained the sulfa-
doxine–pyrimethamine, amodiaquine, and either 
azithromycin or placebo for one of the four cycles. 
The child received a photo identification card that 
had a quick response code (known as a QR code) 
that encoded the child’s name, the mother’s name, 
the child’s date of birth, the census number, and 
a randomization number with a check digit. A la-
bel on the large bag also had a QR code that en-
coded the same variables. On the day of admin-
istration of the trial drugs, the QR codes on the 
identification card and on the large bag were 
scanned with a tablet computer to link the child 
to the correct bag. The trial drugs were kept at the 
trial office and were administered under direct 
observation by trial staff.
When the child was seen for administration 
of the trial drugs, if a diagnosis of malaria was 
confirmed with the use of a rapid diagnostic test, 
the child was not given the assigned regimen and 
instead received a dose of artemether–lumefan-
trine. Children with other illnesses were referred 
to a local health center for investigation and 
treatment.
End Points
The primary end point was death or hospital ad-
mission for at least 24 hours that was not due to 
trauma or elective surgery during the intervention 
period. The intervention period was defined as the 
period from the administration of the first dose of 
the first cycle of the trial drugs until 30 days 
after the administration of the first dose of the 
last cycle. For children who did not receive the first 
dose of the first or last cycle, the date that the dose 
was scheduled to be administered was used.
The prespecified secondary end points were 
the individual components of the primary end 
point; death or hospital admission for at least 24 
hours during the entire trial period; parasitologi-
cally confirmed malaria, which was defined as a 
febrile illness (a history of fever within 24 hours 
or a measured temperature of ≥37.5°C) and either 
a positive rapid diagnostic test or a positive blood 
smear; radiographically confirmed pneumonia; 
clinically diagnosed pneumonia or lower respi-
ratory tract infection; gastrointestinal infection; 
nonmalarial fever, which was defined as a febrile 
illness that was not due to malaria, lower or up-
per respiratory tract infection, or gastrointestinal 
infection; and anemia (hemoglobin level, <10 g per 
deciliter) or severe anemia (hemoglobin level, <7 g 
per deciliter) at the end of the malaria-transmis-
sion season. An exploratory analysis was per-
formed to investigate the incidence of skin dis-
eases.
Surveillance
Deaths and hospital admissions were recorded 
throughout the trial period, but only events that 
occurred during the intervention period contrib-
uted to the primary end point. Data regarding 
vital status were updated during an annual census 
and during an exit census that was conducted in 
March 2017. Deaths that occurred outside a 
health facility were assessed with the use of the 
World Health Organization verbal autopsy ques-
tionnaire.11 The trial-group assignments were 
masked for all assessments. Data regarding ad-
verse events that occurred during the week after 
administration of the trial drugs were solicited 
from 800 children (a random selection of 200 chil-
dren from each trial group in each country) on 
day 7 after each cycle in the first year of the trial. 
Details regarding surveillance are provided in the 
Supplementary Appendix.
In addition, 200 children (a random selection 
of 50 children from each trial group in each coun-
try) were visited each week during the malaria-
transmission season for active detection of malaria 
infection. At the end of each malaria-transmission 
season (≥30 days after the administration of the 
first dose of the last cycle of the trial drugs), 
4000 children (a random selection of approxi-
mately 1000 children from each trial group in 
each country) were included in a cross-sectional 
survey to assess the prevalence of malaria para-
sitemia. In addition, at the end of each malaria-
transmission season, blood slides were obtained 
from 500 primary school children 5 to 12 years 
of age who lived in each trial area to provide data 
on the prevalence of malaria parasitemia among 
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children who did not receive seasonal malaria 
chemoprevention.
Statistical Analysis
On the basis of data from previous seasonal ma-
laria chemoprevention trials performed in Burkina 
Faso12 and Mali,13 we assumed that the incidence 
of death or hospital admission that was not due 
to trauma or elective surgery during the malaria-
transmission season would be approximately 15 
per 1000 children who received seasonal malaria 
chemoprevention plus placebo and the rate of 
loss to follow-up would be 10% per year. On the 
basis of these assumptions, we calculated that the 
enrollment of 19,200 children (9600 per country) 
for three malaria-transmission seasons would give 
the trial 90% power to detect a 25% lower inci-
dence of the primary end point with azithromycin 
than with placebo.
The primary analysis was an intention-to-
treat analysis of deaths and hospital admissions 
that occurred during the 4-month intervention 
period each year. The intention-to-treat popula-
tion included all the children who had been 
screened and enrolled in the trial. A per-protocol 
analysis of the primary end point was also per-
formed. Children who were seen on the first day 
of administration of the trial drugs for all four 
cycles of a particular year were included in the 
per-protocol population for that year. All analyses 
of secondary end points were performed on an 
intention-to-treat basis; these analyses were not 
adjusted for multiple comparisons, and thus P val-
ues are not reported for secondary end points.
For each child, person-time at risk was calcu-
lated as the time from the date of enrollment 
until 30 days after the date that the first dose of 
the last cycle was scheduled to be administered. 
If applicable, the following end dates were used 
instead: if the child was lost to follow-up, the date 
that the child was last seen; if the child emigrated, 
the date of permanent emigration; if the child died, 
the date of death; or if the child reached 5 years of 
age, the last day of the trial year in which the child 
reached 5 years of age.
The incidence rate ratio of the primary end 
point was estimated with the use of Poisson re-
gression models, with a gamma-distributed ran-
dom effect to account for clustering of episodes 
within households. Regression models were ad-
justed for trial site and stratified according to 
follow-up time with the use of Lexis expansion. 
As prespecified in the statistical analysis plan, 
effect modification according to trial site and year 
of age was assessed with the use of the likelihood 
ratio test, without adjustment for multiple com-
parisons, since only these two subgroup analyses 
were performed. Prevalence rate ratios were esti-
mated with the use of Poisson regression models, 
with a robust standard error to account for ran-
domization according to household.12
R esult s
Children and Coverage with Seasonal 
Malaria Chemoprevention
In July 2014, a total of 19,578 children from 9618 
households were randomly assigned to receive 
seasonal malaria chemoprevention plus either 
azithromycin (9735 children) or placebo (9843 
children) (Fig. 1). Each year, additional children in 
the specified age range were enrolled (6287 in 
the second year and 5748 in the third year), and 
children who were 5 years of age on August 1 
exited the trial. Because of establishment of new 
households in the trial areas and migration of 
children into households that were originally 
included in the trial, the overall number of chil-
dren in the trial increased each year. At the last 
follow-up visit, there were 10,885 children in the 
group that received seasonal malaria chemopre-
vention plus azithromycin and 10,852 in the group 
that received seasonal malaria chemoprevention 
plus placebo.
The two trial groups were well matched with 
regard to baseline characteristics (Table S1 in the 
Supplementary Appendix). Coverage with long-
lasting insecticide-treated bed nets was high and 
similar in the two groups. The percentage of chil-
dren who received at least three directly observed 
cycles of the assigned regimen was 92.8% in the 
first year, 86.8% in the second year, and 84.3% 
in the third year (Table S2 in the Supplementary 
Appendix).
Efficacy
In the intention-to-treat analysis, the overall num-
ber of deaths and hospital admissions that were 
not due to trauma or elective surgery was similar 
in the two trial groups: 250 in the azithromycin 
group and 238 in the placebo group (events per 
1000 child-years at risk, 24.8 vs. 23.5; incidence 
rate ratio, 1.1; 95% confidence interval [CI], 0.88 
to 1.3) (Table 1). In the per-protocol analysis, the 
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overall number was 173 in the azithromycin 
group and 158 in the placebo group (events per 
1000 child-years at risk, 19.8 vs. 18.2; incidence 
rate ratio, 1.1; 95% CI, 0.88 to 1.4) (Table S3 in 
the Supplementary Appendix).
In the intention-to-treat population, there was 
evidence of an interaction between trial group 
and trial site (P = 0.02 by the likelihood ratio 
test). The incidence of the primary end point was 
higher in the azithromycin group than in the 
placebo group in Burkina Faso (incidence rate 
ratio, 1.3; 95% CI, 1.0 to 1.7) but not in Mali 
(incidence rate ratio, 0.84; 95% CI, 0.64 to 1.1). 
The incidence of the primary end point according 
to year of age was similar in the two trial groups, 
both in the entire trial population (P = 0.44 for 
interaction by the likelihood ratio test) and in 
each country individually (Fig. 2, and Figs. S2 and 
S3 in the Supplementary Appendix). The causes 
of deaths and hospital admissions that occurred 
during the intervention period and during the 
entire trial period are shown in Tables S4 through 
S9 in the Supplementary Appendix. Malaria was 
the most prominent cause of death and hospital 
admission in each trial group.
The incidence of clinic visits for the following 
events was lower with antimalarial agents plus 
azithromycin than with antimalarial agents plus 
placebo: gastrointestinal infections (incidence rate 
ratio, 0.85; 95% CI, 0.79 to 0.91), upper respiratory 
tract infections (incidence rate ratio, 0.85; 95% CI, 
0.81 to 0.90), and nonmalarial fevers (incidence 
Figure 1. Screening, Randomization, and Follow-up.
19,578 Children from 2014 census
underwent randomization
Additional 6287 from 2015 census
underwent randomization
9843 Were assigned to receive seasonal
malaria chemoprevention+placebo
9735 Were assigned to receive seasonal
malaria chemoprevention+azithromycin
205 Were not seen at first
screening
240 Were not seen at first
screening
9603 Were included in follow-up
for 2014 malaria season
9530 Were included in follow-up
for 2014 malaria season
62 Died
100 Left trial area
1792 Reached 5 yr of age
49 Died
111 Left trial area
1760 Reached 5 yr of age
10,760 Were included in follow-up
for 2015 malaria season
10,678 Were included in follow-up
for 2015 malaria season
Additional 5748 from 2016 census
underwent randomization
67 Died
237 Left trial area
4 Were lost to follow-up
2080 Reached 5 yr of age
62 Died
253 Left trial area
1 Was lost to follow-up
2166 Reached 5 yr of age
11,047 Were included in follow-up
for 2016 malaria season
11,073 Were included in follow-up
for 2016 malaria season
27 Died
146 Left trial area
15 Were lost to follow-up
31 Died
147 Left trial area
17 Were lost to follow-up
10,852 Were included in follow-up
at end of trial
10,885 Were included in follow-up
at end of trial
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 7, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 6
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
rate ratio, 0.79; 95% CI, 0.73 to 0.87) (Table 2). 
An exploratory analysis showed that, among 
children who had a clinic visit for nonmalarial 
fever, 269 children in the azithromycin group 
and 442 children in the placebo group had a skin 
condition (events per 1000 child-years at risk, 26.6 
vs. 43.6; incidence rate ratio, 0.61; 95% CI, 0.53 
to 0.73). Among children who had a clinic visit 
for nonfebrile illness, 428 children in the azithro-
mycin group and 556 children in the placebo 
group had a skin condition (events per 1000 child-
years at risk, 42.4 vs. 54.8; incidence rate ratio, 
0.77; 95% CI, 0.67 to 0.89). The number of chil-
dren with a skin condition that most likely had 
a bacterial cause was substantially lower in the 
azithromycin group than in the placebo group, 
especially among those with nonmalarial fever 
(66 vs. 145; events per 1000 child-years at risk, 
6.54 vs. 14.3; incidence rate ratio, 0.46; 95% CI, 
0.33 to 0.62).
End Point
Seasonal Malaria 
Chemoprevention 
plus Placebo
Seasonal Malaria 
Chemoprevention 
plus Azithromycin
Incidence 
Rate Ratio 
(95% CI) P Value
P Value for 
Interaction
No. of 
Events
Events per 1000 
Child-Yr at Risk 
(95% CI)
No. of 
Events
Events per 1000 
Child-Yr at Risk 
(95% CI)
Hospital admission or death
Both sites 238 23.5 (20.7–26.6) 250 24.8 (21.9–28.0) 1.1 (0.88–1.3) 0.57 0.02
Burkina Faso 101 20.2 (16.6–24.6) 134 26.6 (22.4–31.5) 1.3 (1.0–1.7) — —
Mali 137 26.6 (22.5–31.5) 116 23.0 (19.2–27.6) 0.84 (0.64–1.1) — —
Hospital admission
Both sites 188 18.5 (16.1–21.4) 184 18.2 (15.8–21.1) 0.98 (0.79–1.2) — 0.13
Burkina Faso 86 17.2 (13.9–21.2) 100 19.8 (16.3–24.1) 1.2 (0.85–1.6) — —
Mali 102 19.8 (16.3–24.1) 84 16.6 (13.4–20.6) 0.83 (0.61–1.1) — —
Death
Both sites 50 4.93 (3.73–6.50) 66 6.54 (5.14–8.32) 1.3 (0.92–1.9) — 0.02
Burkina Faso 15 3.00 (1.81–4.98) 34 6.74 (4.81–9.43) 2.3 (1.2–4.1) — —
Mali 35 6.80 (4.88–9.47) 32 6.34 (4.48–8.96) 0.93 (0.58–1.5) — —
*  Data were obtained during the intervention period of each malaria-transmission season, which was defined as the period from the adminis-
tration of the first dose of the first cycle of the trial drugs until 30 days after the administration of the first dose of the last cycle. For all end 
points except the primary end point, confidence intervals for the rate ratios were not adjusted for multiple comparisons; inferences drawn 
from these intervals may not be reproducible. Rate ratios and the P value were estimated with the use of Poisson regression models with 
random effects. P values for interaction were estimated with the use of the likelihood ratio test.
Table 1. Incidence of Death or Hospital Admission That Was Not Due to Trauma or Elective Surgery during Three Successive Malaria-
Transmission Seasons in the Intention-to-Treat Population.*
Figure 2. Incidence of Death or Hospital Admission That Was Not Due to 
Trauma or Elective Surgery during Three Successive Malaria-Transmission 
Seasons in Burkina Faso and Mali.
I bars indicate 95% confidence intervals.
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Among children who were randomly selected 
for weekly follow-up visits during the intervention 
period, the prevalence of malaria parasitemia 
ranged from 3 to 7% and was similar in the two 
groups. At the end of the malaria-transmission 
season, the prevalence of malaria parasitemia 
ranged from 4 to 10% and the prevalence of ane-
mia ranged from 20 to 26%. For both variables, 
results were similar in the two trial groups (Ta-
ble 3). Among primary school children who lived 
in the trial areas and did not receive seasonal 
malaria chemoprevention, the prevalence of ma-
laria parasitemia at the end of the malaria-trans-
mission season ranged from 50 to 65% (Table 3).
Safety
No severe adverse events that were judged by 
investigators to be related to the trial drugs were 
recorded. Diarrhea was the most frequent adverse 
event reported after administration of the trial 
drugs. The incidences of diarrhea and of other 
adverse events that occurred during the week af-
ter administration of the trial drugs were similar 
in the two trial groups (Table S10 in the Supple-
mentary Appendix).
Discussion
In this trial, the incidence of death or hospital 
admission that was not due to trauma or elective 
surgery did not differ significantly between chil-
dren who received seasonal malaria chemopreven-
tion plus azithromycin and children who received 
seasonal malaria chemoprevention plus placebo 
when data from Burkina Faso and Mali were com-
bined for the primary analysis. However, the inci-
dence of death or hospital admission was higher 
with azithromycin than with placebo in Burkina 
Faso but not in Mali. No plausible mechanism to 
explain this difference was found, and given the 
borderline increased incidence in Burkina Faso, it 
may be a chance finding. The incidences of gastro-
intestinal infections, upper respiratory tract infec-
tions, and nonmalarial fevers were lower with 
azithromycin than with placebo (by 15%, 15%, and 
21%, respectively), and in an exploratory analysis, 
Event
Seasonal Malaria 
Chemoprevention 
plus Placebo
Seasonal Malaria 
Chemoprevention 
plus Azithromycin
Incidence 
Rate Ratio 
(95% CI)
No. of 
Events
Events per 1000 
Child-Yr at Risk 
(95% CI)
No. of 
Events
Events per 1000 
Child-Yr at Risk 
(95% CI)
Parasitologically confirmed malaria 10,845 1068.7 (1048.8–1089.0) 10,394 1029.5 (1009.9–1049.4) 0.97 (0.93–1.0)
Radiographically confirmed pneumonia 13 1.3 (0.74–2.2) 14 1.4 (0.82–2.3) 1.1 (0.49–2.4)
Clinical pneumonia or lower respiratory 
tract infection
339 33.4 (30.0–37.2) 285 28.2 (25.1–31.7) 0.84 (0.70–1.0)
Gastrointestinal infection 1,985 195.6 (187.2–204.4) 1,647 163.1 (155.4–171.2) 0.85 (0.79–0.91)
Upper respiratory tract infection† 5,763 567.9 (553.4–582.8) 4,893 484.6 (471.2–498.4) 0.85 (0.81–0.90)
Nonmalarial fever‡ 1,424 140.3 (133.2–147.8) 1,122 111.1 (104.8–117.8) 0.79 (0.73–0.87)
Trauma† 128 12.6 (10.6–15.0) 135 13.4 (11.3–15.8) 1.1 (0.85–1.4)
Clinical malnutrition† 9 0.89 (0.46–1.7) 5 0.50 (0.21–1.19) 0.56 (0.19–1.7)
Other outpatient visit† 1,377 135.7 (128.7–143.1) 1,132 112.1 (105.8–118.8) 0.83 (0.76–0.91)
*  Data were obtained during the intervention period of each malaria-transmission season, which was defined as the period from the adminis-
tration of the first dose of the first cycle of the trial drugs until 30 days after the administration of the first dose of the last cycle. Confidence 
intervals for the rate ratios were not adjusted for multiple comparisons; inferences drawn from these intervals may not be reproducible.
†  This event was not a prespecified secondary end point.
‡  Nonmalarial fever was defined as a temperature of at least 37.5°C or a history of fever within 24 hours that was not due to malaria, lower or 
upper respiratory tract infection, or gastrointestinal infection.
Table 2. Incidence of Clinical Events Treated at Health Centers or by Community Health Workers during Three Successive Malaria-
Transmission Seasons in Burkina Faso and Mali in the Intention-to-Treat Population.*
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Variable
Seasonal Malaria 
Chemoprevention 
plus Placebo
Seasonal Malaria 
Chemoprevention 
plus Azithromycin
Prevalence 
Rate Ratio 
(95% CI)
no./total no. (%)
Among children in the trial
Malaria parasitemia, according to data from weekly visits during 
the malaria-transmission season
2014 49/1507 (3.25) 44/1483 (2.97) 0.92 (0.62–1.4)
2015 107/1563 (6.85) 103/1539 (6.69) 0.98 (0.75–1.3)
2016 81/1598 (5.07) 90/1589 (5.66) 1.1 (0.84–1.5)
Malaria parasitemia, according to data from cross-sectional sur-
veys at the end of the malaria-transmission season
2014 84/1997 (4.21) 67/2012 (3.33) 0.79 (0.57–1.1)
2015 187/1966 (9.51) 171/2010 (8.51) 0.89 (0.73–1.1)
2016 173/1982 (8.73) 212/1999 (10.6) 1.2 (1.0–1.5)
Anemia, according to data from cross-sectional surveys at the 
end of the malaria-transmission season
2014
Hemoglobin, <10 g/dl 432/1997 (21.6) 407/2012 (20.2) 0.93 (0.83–1.1)
Hemoglobin, <7 g/dl 16/1997 (0.80) 10 /2012 (0.50) 0.62 (0.28–1.4)
2015
Hemoglobin, <10 g/dl 411/1966 (20.9) 399/2010 (19.9) 0.95 (0.84–1.1)
Hemoglobin, <7 g/dl 20/1966 (1.02) 17/2010 (0.85) 0.83 (0.44–1.6)
2016
Hemoglobin, <10 g/dl 516/1982 (26.0) 505/1999 (25.3) 0.97 (0.87–1.1)
Hemoglobin, <7 g/dl 20/1982 (1.01) 18/1999 (0.90) 0.89 (0.47–1.7)
Burkina Faso Mali Both Sites
no./total no. (%) no./total. no.
Among primary school children
Malaria parasitemia, according to data from blood samples at 
the end of the malaria-transmission season
2014
Any parasitemia 308/497 (62.0) 294/496 (59.3) 602/993
Density, >5000/mm3 23/497 (4.6) 31/496 (6.3) 54/993
2015
Any parasitemia 324/529 (61.2) 326/500 (65.2) 650/1029
Density, >5000/mm3 29/529 (5.5) 47/500 (9.4) 76/1029
2016
Any parasitemia 251/500 (50.2) 268/500 (53.6) 519/1000
Density, >5000/mm3 28/500 (5.6) 26/500 (5.2) 54/1000
*  The primary school children lived in the trial areas and did not receive seasonal malaria chemoprevention. Confidence intervals for the rate 
ratios were not adjusted for multiple comparisons; inferences drawn from these intervals may not be reproducible.
Table 3. Prevalence of Malaria Parasitemia and Anemia among Children in the Trial and Prevalence of Malaria Parasitemia among Primary 
School Children.*
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the incidence of skin diseases, especially those that 
most likely had a bacterial cause, was also lower 
with azithromycin; these results are consistent 
with findings of previous studies in which azithro-
mycin was used in trachoma control programs.4-8
The findings of our trial contrast with those 
of the MORDOR (Mortality Reduction after Oral 
Azithromycin) trial conducted in Malawi, Niger, 
and Tanzania, in which azithromycin was given 
to children younger than 5 years of age twice a 
year for 2 years and then was associated with a 
13.5% (95% CI, 6.7 to 19.8) lower overall all-cause 
mortality than placebo, with the effect being most 
marked in Niger.14 Children who were assigned to 
the azithromycin group in our trial had greater 
exposure to azithromycin than those in the 
MORDOR trial (four courses each year for up to 
3 years in our trial, as compared with two cours-
es each year for 2 years in the MORDOR trial); 
such enhanced exposure might have been expected 
to have an effect on mortality that was at least 
equal to the effect seen in the MORDOR trial, 
but this was not the case.
There are several possible explanations for 
the different outcomes of these two trials. One 
possible explanation is that azithromycin, which 
has antimalarial activity,15 contributed to decreased 
mortality in the MORDOR trial partly through its 
effect on malaria, and this benefit was lost when 
an additional, effective antimalarial combination 
was given at the same time as azithromycin. How-
ever, the effect of azithromycin on malaria has 
been inconsistent when azithromycin has been 
given in mass drug administration programs.16-18 
In addition, all the children in our trial received 
sulfadoxine–pyrimethamine, which has weak an-
timicrobial properties, and this may have reduced 
the potential benefit of adding another antimicro-
bial to the regimen. Finally, coverage with a pneu-
mococcal conjugate vaccine was high among the 
children in our trial, and this may have reduced 
the potential benefit of azithromycin in lowering 
mortality from pneumonia.
In the MORDOR trial, the greatest effect of 
azithromycin on all-cause mortality was seen in 
the first year of life.14 This finding suggests that, 
despite the results of this trial, the addition of 
azithromycin to the sulfadoxine–pyrimethamine 
used for intermittent prevention of malaria in 
infants19 is an option worth investigating in coun-
tries with a high malaria burden in the first year 
of life.
The prevalence of malaria at the end of the 
malaria-transmission season was substantially 
lower among children who were enrolled in our 
trial than among primary school children who 
were living in the same areas and were not re-
ceiving seasonal malaria chemoprevention, a find-
ing that indicates that seasonal malaria chemopre-
vention with sulfadoxine–pyrimethamine plus 
amodiaquine was having a major protective effect 
against malaria in these populations. Nevertheless, 
the proportion of deaths and hospital admissions 
that were attributable to malaria was still large in 
both trial groups, despite good access to treatment 
and high coverage with long-lasting insecticide-
treated bed nets. Effective control of malaria in 
these and other, similar areas necessitates addi-
tional control measures.
A limitation of the trial is that randomization 
was performed according to household rather than 
village; randomization according to household re-
duced the potential for bias but precluded the 
potential for a herd effect that might have occurred 
had randomization according to village been per-
formed. Only limited safety data were obtained 
because seasonal malaria chemoprevention with 
sulfadoxine–pyrimethamine plus amodiaquine and 
mass administration of azithromycin have now 
been given to millions of children with no major 
safety concerns.
In conclusion, among children in Burkina Faso 
and Mali, the addition of azithromycin to the anti-
malarial agents used for seasonal malaria chemo-
prevention did not result in a lower incidence of 
death or hospital admission that was not due to 
trauma or surgery than antimalarial agents plus 
placebo. We also noted that the incidences of 
clinic visits for gastrointestinal infections, upper 
respiratory tract infections, and nonmalarial fe-
brile illnesses, without adjustment for multiple 
comparisons, were lower among children who re-
ceived antimalarial agents plus azithromycin than 
among those who received antimalarial agents 
plus placebo.
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